ABSTRACT
Objective To evaluate the value of rs61330082 and rs4730153 polymorphisms of Visfatin locus for the diagnosis of type 2 diabetes mellitus(T2DM)in a high-risk population.Methods SNPscanTM high-throughput single nucleotide polymorphism typing technique was used to genotype Visfatin gene loci rs61330082 and rs4730153 in 346 T2DM patients(T2DM group)and 1426 normal controls(NC group).Logistic regression analysis was used to analyze T2DM risk factors.ROC curves were used to analyze the optimal cut-off values of Visfatin gene rs61330082 and rs4730153 for the diagnosis of T2DM.Results The proportion of women,age,obesity,smoking,hypertension,FPG,HbA1c and TG were higher in T2DM group than those in NC group(P<0.01)and HDL-C was lower than in NC group(P<0.01).The frequency of G allele and GG genotype was higher in T2DM group compared with NC group(P<0.05).Logistic regression analysis showed that age,female,obesity,hypertension,TG,and GG genotype at rs4730153 locus were risk factors for T2DM,HDL-C was a protective factor for T2DM.The area under the ROC curve of GG genotype at Visfatin rs4730153 mutation for diagnosis of T2DM was 0.668 and the optimal cut-off point for predicting T2DM was 20.04%,with sensitivity 60.1%and specificity 66.1%,respectively.Conclusion The GG genotype of Visfatin gene rs4730153 locus is associated with the risk of T2DM and can beused as a candidate gene for predicting phenotype of T2DM.
ABSTRACT
SUMMARY OBJECTIVE: Nonalcoholic fatty liver disease is a chronic liver disease and a growing global epidemic. The aim of this study was to investigate the association between a visfatin gene (NAMPT) variant and nonalcoholic fatty liver disease, owing to the connection between this disease and insulin resistance, obesity, inflammation, and oxidative stress, and the role of visfatin in these metabolic disorders. METHODS: In the present case-control study, we enrolled 312 genetically unrelated individuals, including 154 patients with biopsy-proven nonalcoholic fatty liver disease and 158 controls. The rs2058539 polymorphism of NAMPT gene was genotyped using the PCR-RFLP method. RESULTS: Genotype and allele distributions of NAMPT gene rs2058539 polymorphism conformed to the Hardy-Weinberg equilibrium both in the case and control groups (p>0.05). The distribution of NAMPT rs2058539 genotypes and alleles differed significantly between the cases with nonalcoholic fatty liver disease and controls. The "CC" genotype of the NAMPT rs2058539 compared with "AA" genotype was associated with a 2.5-fold increased risk of nonalcoholic fatty liver disease after adjustment for confounding factors [p=0.034; odds ratio (OR)=2.52, 95% confidence interval (CI)=1.36-4.37]. Moreover, the NAMPT rs2058539 "C" allele was significantly overrepresented in the nonalcoholic fatty liver disease patients than controls (p=0.022; OR=1.77, 95%CI=1.14-2.31). CONCLUSION: Our findings indicated for the first time that the NAMPT rs2058539 "CC" genotype is a marker of increased nonalcoholic fatty liver disease susceptibility; however, it needs to be supported by further investigations in other populations.
ABSTRACT
The purpose of this study was to look at the serum levels of Visfatinin non-obese ordinary circulatory strain, non-obese hypertension and obesity hypertension. Research plan was Comparative cross sectional study. The Place and span was collaborating with the Institute of Medical Science in Lahore at the Graduate School of Medicine Laboratory of Lahore. This research included 81 subjects, each separated into 3 gatherings: non-obese normotensive, non-obese hypertensive and obesity hypertension. Circulatory strain level, BMI (Body Mass Index) and WHR (Waist to Hip Ratio) were estimated. Fasting blood tests were gathered to evaluate Visfatin levels in the serum. The results showed that the Mean serum Visfatin levels of 70.97 ± 50.30 ng/ml were seen in obese hypertensive patients contrasted with 33.71 ± 10.66 ng/ml and 5.21 ± 3.57 ng/ml for non-obese hypertensive and non-obese ordinary circulatory strain. It is concluded that Serum Visfatin levels can be utilized as biomarkers for assessing hypertension in obese and non-obese patients.
ABSTRACT
Background: Acne is a chronic inflammatory disease of the pilosebaceous units, of multifactorial pathogenesis, one of which could be an adipokine such as visfatin. Aim: The aim of this study was to study visfatin expression both in lesional skin and serum, of acne patients versus healthy controls. The secondary aim was to study the relationship of visfatin levels with dyslipidemia/metabolic syndrome. Methods: This study included 30 patients with moderate and severe acne vulgaris and 30 age- and sex-matched healthy controls. Serum and tissue visfatin were estimated by enzyme-linked immune-sorbent assay. Clinical and laboratory examinations were done to assess the anthropometric data and various criteria of metabolic syndrome. Results: Tissue and serum visfatin levels were significantly higher in patients as compared to healthy controls. Tissue visfatin levels were significantly higher than its serum levels in both patients and controls. Serum visfatin was significantly higher in overweight individuals. No correlations were found between tissue and serum visfatin levels in both patients and controls. Moreover, serum and tissue visfatin levels did not correlate to any of the lipid profile parameters or criteria of metabolic syndrome in acne patients. Limitations: The study had a small sample size and did not localize the exact source of tissue visfatin. Polycystic ovary syndrome PCOS was not evaluated. Conclusion: Visfatin is an important proinflammatory adipokine, with significantly higher expression in acne patients. Tissue rather than serum visfatin might play a key role in acne
ABSTRACT
Objective@#To investigate the effects of the link between overweight/obesity and type 2 diabetes mellitus (T2DM) on leptin and visfatin levels.@*Methods@#Males without T2DM and male patients with T2DM hospitalized in Lishui Municipal Central Hospital from January to June, 2017 were enrolled. Subjects' age and medical history of diseases were collected. The height and body weight were measured, and the body mass index (BMI) was estimated. The leptin and visfatin levels were determined, and compared between patients with and without T2DM, and between patients with and without overweight/obesity. The effect of the link between overweight/obesity and T2DM on leptin and visfatin levels was examined using a generalized linear regression model.@*Results@#There were 66 patients with T2DM, with a mean age of (49.70±9.45) years and a mean diabetes duration of (4.99±4.46) years, and there were 64 patients without T2DM, with a mean age of (43.89±0.20) years. The leptin [ (3.17±0.36) vs. (3.03±0.30) ng/mL; t=2.387, P=0.018] and visfatin levels [ (29.14±3.16) vs. (21.81±3.32) ng/mL; t=12.900, P<0.001] were significantly greater in T2DM patients than in patients without T2DM. The leptin level was significantly greater in patients with overweight/obesity than in those without overweight/obesity [ (3.27±0.32) vs. (2.92±0.26) ng/mL; t=6.634, P<0.001], and the visfatin level was significantly lower in patients with overweight/obesity than in those without overweight/obesity [(24.38±5.14) vs. (26.71±4.36) ng/mL; t=2.780, P=0.006]. Generalized linear regression analysis showed interacting effects of overweight/obesity and T2DM on leptin (β=0.286, P=0.003) and visfatin levels (β=2.709, P=0.008).@*Conclusion@#The interaction between overweight/obesity and T2DM affects leptin and visfatin levels.
ABSTRACT
【Objective】 To explore the role of visfatin-nicotinamide phosphoribosyl transferase (Nampt) axis in the progression of epithelial ovarian cancer (EOC) and its effect on the patients’ prognosis. 【Methods】 Immunohistochemical analysis was used to detect the expression of Nampt protein in tissues from epithelial ovarian cancer and normal ovary; ELISA was used to determine the level of visfatin in serum. Then the two were further analyzed to estimate their effects on clinicopathological characteristics and the EOC patients’ overall survival. 【Results】 The mean level of serum visfatin in these EOC patients was significantly elevated compared with that of the patients with benign ovarian tumors and normal population. ROC curve analysis showed that the area under curve (AUC) of serum visfatin for diagnosis of EOC was 0.744, with a cut-off value of 5.95 ng/mL. Serum visfatin of the EOC patients was related to T, N and FIGO stage (P<0.05), and was positively correlated with CA125 (rs=0.389, P=0.001). The rate of Nampt positive expression in tissues from EOC was significantly increased and correlated with FIGO stage and serum visfatin (P<0.05). Nampt protein expression in EOC was positively correlated with serum visfatin level (rs=0.55, P<0.001). The 1-year, 3-year and 5-year survival rate of these patients with EOC was 98.6%, 74.3% and 34.3%, respectively. Survival analysis demonstrated that the overall survival of these patients was related to T, N, FIGO stage, serum visfatin and Nampt expression in EOC, and both FIGO stage and Nampt expression were independent prognostic factors (P<0.05). 【Conclusion】 The overall survival of these EOC patients was related to T, N, FIGO stage, serum visfatin and Nampt expression, and FIGO stage and Nampt expression are independent factors predicting the outcome. This highlights that visfatin-Nampt axis promotes the progression of epithelial ovarian cancer and affects the prognosis of EOC patients.
ABSTRACT
ABSTRACT Objective: Oral glucose tolerance testing (OGTT) is the current recommended approach for the diagnosis of gestational diabetes mellitus (GDM). Visfatin is a type of novel adipokine of interest that mostly participates in glucose metabolism and inflammatory processes. We aim to identify a screening technique for GDM using salivary visfatin levels and to establish this technique's value as a screening method compared to OGTT. Materials and methods: This is a cross-sectional case-control study. The cohort was formed from the saliva samples of pregnant patients in their 24th through 28th weeks of gestation. Patients were divided into two groups depending on their GDM status. OGTT and visfatin test results were compared and subjected to further analysis to establish a cutoff value for visfatin testing. Results: ELISA results indicated a significant difference between patients with GDM compared to patients without GDM; the values were 18.89 ± 9.59 and 12.44 ± 8.75, respectively (p: 0.007). A cutoff value of 10.5 ng/mL can be used to detect GDM with 78% sensitivity and 51% specificity. Conclusion: Salivary visfatin levels were significantly higher in patients with GDM. The existence of a differential in the concentration of visfatin in saliva can be utilized to develop a new screening method for GDM.
Subject(s)
Humans , Female , Pregnancy , Saliva/chemistry , Cytokines/analysis , Diabetes, Gestational/diagnosis , Nicotinamide Phosphoribosyltransferase/analysis , Blood Glucose , Case-Control Studies , Cross-Sectional StudiesABSTRACT
ABSTRACT Objective: Visfatin may regulate a variety of physiological functions and it has great potential to significantly enhance our knowledge of the treatment of metabolic syndrome. Metabolic syndrome (MS) refers to metabolic abnormalities, such as abdominal obesity, dyslipidemia, high low-density cholesterol, high blood pressure and diabetes, and physical activity is an important factor for the management of MS. Therefore, the purpose of this study is to investigate the effects of visfatin on MS and MS risk factors through differences in aerobic exercise intensity and exercise type based on the premise of the same amount of exercise (energy expenditure of 400 kcal per day). Method: Thirty two obese, middle-aged women were randomly assigned to exercise intensity groups VO2max 50% (MAE, n=8) and VO2max 80% (VAE, n=8) and to type of exercise groups VO2max 50% + TRX (MARE, n=8) and VO2max 80% + TRX (VARE, n=8). The exercise program was performed 5 times a week. The data was analyzed using two-way repeated measures ANOVA and post-hoc tests within groups with LSD. Results: Body weight (p<.01 and p<.001) and % body fat (p<.05 and p<.01) significantly decreased in all groups and visfatin only increased significantly after exercise in the VARE group (p<.05). TG, glucose, and waist circumstance (p<.05, p<.01, and p<.001) significantly decreased in all groups and HDL-C (p<.05) only increased significantly after exercise only in the MARE group. Conclusion: These results suggest that, in spite of differences in exercise intensity and exercise type, exercise is effective in improving obesity and MS risk factors, but further research is needed on the exact mechanisms of visfatin. Level of evidence I; Therapeutic Studies Investigating the Results of Treatment .
RESUMEN Objetivo: La visfatina puede regular diversas funciones fisiológicas y tiene gran potencial para mejorar significativamente nuestro conocimiento sobre el tratamiento del síndrome metabólico. El síndrome metabólico (SM) se refiere a anormalidades metabólicas, como obesidad abdominal, dislipidemia, colesterol de baja densidad elevado, hipertensión y diabetes, siendo la actividad física un factor importante para el manejo del SM. Siendo así, el objetivo de este estudio es investigar los efectos de la visfatina sobre los factores de riesgo de SM por medio de diferencias de la intensidad de ejercicios aeróbicos y del tipo de ejercicio, con base en la premisa de misma cantidad de ejercicio (gasto energético de 400 kcal por día). Método: Treinta y dos mujeres obesas de media edad fueron aleatoriamente designadas para grupos de intensidad de ejercicio con VO2máx de 50% (EAM, n = 8) y VO2máx de 80% (EAV, n = 8) y grupos con VO2máx de 50% + ERC (EARM, n = 8) y VO2máx de 80% + ERC (EARV, n = 8). El programa de ejercicios fue realizado cinco veces por semana. Los datos fueron analizados con ANOVA de dos vías con medidas repetidas y tests post-hoc en los grupos con DMS. Resultados: El peso corporal (p < 0,01 y p < 0,001) y porcentual de grasa corporal (p < 0,05 y p < 0,01) disminuyeron significativamente en todos los grupos y la visfatina sólo aumentó significativamente después del ejercicio en el grupo EARV (p < 0,05). Los triglicéridos, la glucosa y la circunferencia de la cintura (p < 0,05, p < 0,01 e p < 0,001) disminuyeron significativamente en todos los grupos y el HDL-C (p < 0,05) sólo aumentó significativamente después del ejercicio sólo en el grupo EARM. Conclusión: Esos resultados sugieren que, a pesar de las diferencias de intensidad y tipo de los ejercicios, los mismos son eficaces para mejorar la obesidad y los factores de riesgo del SM, por ende, son necesarias más investigaciones sobre los mecanismos exactos de la visfatina. Nivel de Evidencia I; Estudios terapéuticos - Investigación de los resultados del tratamiento .
RESUMO Objetivo: A visfatina pode regular diversas funções fisiológicas e tem grande potencial para aprimorar significativamente nosso conhecimento sobre o tratamento da síndrome metabólica. A síndrome metabólica (SM) refere-se a anormalidades metabólicas, como obesidade abdominal, dislipidemia, colesterol de baixa densidade elevado, hipertensão e diabetes, sendo a atividade física um fator importante para o manejo da SM. Assim sendo, o objetivo deste estudo é investigar os efeitos da visfatina sobre os fatores de risco de SM por meio de diferenças da intensidade de exercícios aeróbicos e do tipo de exercício, com base na premissa de mesma quantidade de exercício (gasto energético de 400 kcal por dia). Método: Trinta e duas mulheres obesas de meia-idade foram randomicamente designadas para grupos de intensidade de exercício com VO2máxde 50% (EAM, n = 8) e VO2máxde 80% (EAV, n = 8) e grupos com VO2máxde 50% + ERC (EARM, n = 8) e VO2máxde 80% + ERC (EARV, n = 8). O programa de exercícios foi realizado 5 vezes por semana. Os dados foram analisados com ANOVA de duas vias com medidas repetidas e testes post-hoc nos grupos com DMS. Resultados: O peso corporal (p < 0,01 e p < 0,001) e percentual de gordura corporal (p < 0,05 e p < 0,01) diminuíram significativamente em todos os grupos e a visfatina só aumentou significativamente depois do exercício no grupo EARV (p < 0,05). Triglicérides, glicose e circunferência da cintura (p < 0,05, p < 0,01 e p < 0,001) diminuíram significativamente em todos os grupos e o HDL-C (p < 0,05) só aumentou significativamente depois o exercício apenas no grupo EARM. Conclusão: Esses resultados sugerem que, apesar das diferenças de intensidade e tipo dos exercícios, eles são eficazes para melhorar a obesidade e os fatores de risco da SM, porém, são necessárias mais pesquisas sobre os mecanismos exatos da visfatina. Nível de Evidência I; Estudos terapêuticos - Investigação dos resultados do tratamento .
Subject(s)
Humans , Female , Adult , Middle Aged , Exercise , Metabolic Syndrome/enzymology , Nicotinamide Phosphoribosyltransferase/metabolism , Obesity/enzymology , Oxygen Consumption , Anthropometry , Risk Factors , Metabolic Syndrome/blood , Obesity/bloodABSTRACT
Objective:To investigate the correlation between thyroid function index and serum visfatin in patients with acute pancreatitis (AP).Methods:Using a prospective design, 65 patients with AP treated in Binzhou People's Hospital from December 2017 to December 2019 were selected as the research subjects. They were divided into mild acute pancreatitis (MAP) group ( n = 35) and severe acute pancreatitis (SAP) group ( n = 30) according to the acute physiology and chronic health Ⅱ (APACHE Ⅱ) score ( < 8, ≥8 scores). At the same time, 40 healthy people were selected as the control group. The serum levels of free thyroxine (FT 4), free triiodothyronine (FT 3) and thyrotropin (TSH) were measured by chemiluminescence immunoassay. Radioimmunoassay was used to measure serum reverse triiodothyronine (rT 3) level, and enzyme-linked immunosorbent assay was used to measure serum visfatin level. Pearson method was used to analyze the correlation between thyroid function index and serum visfatin in patients with AP. Results:The FT 4 [(14.02 ± 3.63), (15.68 ± 3.05) pmol/L], FT 3 [(2.34 ± 0.80), (3.66 ± 0.65) pmol/L], and TSH levels [(2.78 ± 0.85), (3.10 ± 0.57) mU/L] in SAP and MAP groups were significantly lower than those in control group [(17.03 ± 3.96), (6.04 ± 1.55) pmol/L, (4.88 ± 2.30) mU/L, P < 0.05], but the rT 3 levels [(1.63 ± 1.12), (1.23 ± 0.26) nmol/L] were significantly higher than that in control group [(0.97 ± 0.28) nmol/L, P < 0.05]. There was significant difference in serum FT 3 levels between SAP and MAP groups ( P < 0.05). The serum visfatin levels of SAP, MAP and control groups were (10.75 ± 2.92), (3.70 ± 1.73), (2.30 ± 1.31) ng/ml, the difference between the three groups was statistically significant ( F = 67.174, P < 0.05). The serum visfatin levels in SAP and MAP groups were higher than that in control group, and that in SAP group was higher than that in MAP group ( P < 0.05). There were negative correlations between serum FT 3 level and visfatin level in SAP and MAP groups ( r = - 0.672, - 0.610, P < 0.05). Conclusions:The serum visfatin level and thyroid function index of AP patients are abnormal. The levels of FT 3 and visfatin are correlated with the severity of AP patients, and there is a negative correlation between the levels of FT 3 and visfatin. Detection of thyroid function index is helpful to judge the AP patient's condition.
ABSTRACT
OBJECTIVE@#To explore the effect of electro-acupuncture (EA) on glucose and lipid metabolism in unmarried patients with polycystic ovary syndrome (PCOS).@*METHODS@#Fifty-four PCOS patients were equally randomized into true acupuncture group and sham acupuncture group (control) for totally 16 weeks of treatment by random method with a computerized randomization program. Patients in true acupuncture group accepted traditional acupuncture methods with EA and two sets of acupoint groups were used alternatively. The first set consisted of Zhongji (CV 3), Qihai (CV 6), Guilai (ST 29), Sanyinjiao (SP 6), Yinlingquan (SP 9), Hegu (LI4) and Baihui (GV 20), and the second set consisted of Tianshu (ST 25), ST 29, CV 3, CV 6, SP 6, Taichong (LR 3), Neiguan (PC) 6 and GV 20. Patients in the sham acupuncture group accepted shallow acupuncture methods through EA without electricity at 4 non-meridian points in each shoulder and upper arm. Outcome measures included body mass index (BMI), waist-hip-ratio (WHR), oral glucose tolerance test (OGTT), insulin release test, glucose and lipid metabolism indicators such as total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, adiponectin, leptin, visfatin, resistin, and interleukin (IL-6).@*RESULTS@#Twenty-six subjects in the true acupuncture group and 20 subjects in the sham group completed the clinical trial. After 16 weeks of treatment, no significant difference in the outcome measures were observed between the two groups (P>0.05). However, as compared with baseline data, a reduction in weight, BMI, hipline, WHR, fasting glucose, homeostatic model assessment of insulin sensitivity, visfatin and HDL-C, and an increase in resistin and IL-6 were observed in the true acupuncture group (P<0.05). In addition, a reduction in visfatin and an increase in TC were also observed in the sham group (P<0.05).@*CONCLUSIONS@#Acupuncture may have a beneficial effect in the treatment of PCOS by improving glucose and lipid metabolism. Moreover, the sham acupuncture may be not completely ineffective. Sham acupuncture may improve some of the aspects of the glucose and lipid metabolism of PCOS patients through a placebo effect. (Registration Nos. ChiCTR-TRC-12002529 and NCT01812161).
Subject(s)
Female , Humans , Acupuncture Therapy , Glucose , Insulin Resistance , Lipid Metabolism , Polycystic Ovary Syndrome/therapy , Single PersonABSTRACT
Objective To investigate the expression and correlation of visfatin, hsa-miR-199a and extracellular regulated protein kinase 1/2 (ERK1/2) in colorectal cancer (CRC) tissues. Methods The expression levels of visfatin mRNA and hsa-miR-199a were detected by Real-time PCR in 64 primary cases of radical resection of colorectal cancer who underwent pathological clinical examination in the clinicopathological examination in our hospital center from January 2017 to December 2017, the protein expression levels of visfatin and ERK1/2 were detected by immunohistochemistry and Western blotting. The relative expression levels of hsa-miR-199a in each group were compared according to the expression levels of visfatin and ERK1/2. Results The levels of visfatin gene and protein in colorectal cancer tissue (observation group, 64 cases) were higher than those in normal colorectal cancer (control group, 64 cases), and the expression was consistent. The colorectal cancer tissue(observation group) expression level of hsa-miR-199a was lower than that of normal colorectal tissue(control group), and visfatin mRNA was significantly negatively correlated. The colorectal cancer tissue (observation group) expression of ERK1/2 was higher than normal colorectal tissue (control group) and visfatin was significantly positively correlated. The relative expression of hsa-miR-199a in the visfatin and ERK1/2 positive group was significantly different from that in the test variables. Conclusion The overexpression of visfatin in colorectal cancer affects the down-regulation of hsa-miR-199a and is related to the ERK signaling pathway.
ABSTRACT
@#Diabetic retinopathy(DR)is a chronic retinopathy secondary to diabetes that can cause permanent loss of vision in patients with type 1 and type 2 diabetes. The occurrence of DR is associated with retinal microvascular dysfunction, retinal tissue edema, bleeding, and secondary neovascular proliferation. Studies have shown that patients with diabetes have high expression of visfatin in adipose tissue, liver and kidney, and that the factor may be present in retinal tissue, which has a certain regulatory effect on the development of diabetic retinopathy. This review focuses on the relationship between visfatin and diabetic retinopathy.
ABSTRACT
Objective@#To explore the correlation between serum visfatin level and cardiovascular disease risk factors in patient with polycystic ovary syndrome (PCOS).@*Methods@#A total of 100 PCOS patients (PCOS group) and 50 healthy women (control group) in Wuhan Puren Hospital from July 2016 to July 2018 were selected. In addition, according to the body mass index (BMI), the PCOS patients were divided into obese group (BMI ≥ 25 kg/m2, 57 cases) and non-obese group (BMI < 25 kg/m2, 43 cases). Serum level of visfatin was measured by enzyme-linked immunosorbent assay (ELISA) method, and the correlation between serum visfatin and follicle-stimulating hormone (FSH), luteinizing hormone (LH), testesterone (T), high sensitivity C-reactive protein (hs-CRP), blood lipids and blood glucose was analyzed.@*Results@#Compared with those in control group, the visfatin, BMI, diastolic blood pressure, waist and hip rate, hirsutism F-G score, FSH, LH, T, triglyeride (TG), fasting insulin (FINS), homeostasis model of assessment for insulin resistance index (HOMA-IR) in PCOS group were significantly increased: (103.20 ± 19.15) μg/L vs. (29.56 ± 4.14) μg/L, (25.81 ± 4.17) kg/m2 vs. (21.29 ± 3.74) kg/m2, (81.91 ± 10.32) mmHg (1 mmHg = 0.133 kPa) vs. (68.29 ± 7.57) mmHg, 0.91 ± 0.14 vs. 0.82 ± 0.13,(13.41 ± 2.91) scores vs. (5.98 ± 1.01) scores, (12.78 ± 1.98) U/L vs. (11.95 ± 1.51) U/L, (15.84 ± 3.16) U/L vs. (12.94 ± 1.53) U/L, (2.98 ± 0.32) nmol/L vs. (1.17 ± 0.20) nmol/L, (1.89 ± 0.43) mmol/L vs. (1.21 ± 0.11) mmol/L, (18.40 ± 2.98) mU/L vs. (11.23 ± 2.10) mU/L, 4.25 ± 0.86 vs. 2.51 ± 0.55; the high density lipoprotein-cholesterol (HDL-C) and ISI were significantly decreased: (1.46 ± 0.23) mmol/L vs. (1.55 ± 0.27) mmol/L and 0.011 ± 0.002 vs. 0.019 ± 0.005, and there were statistical differences (P<0.01 or <0.05). In addition, compared with those in non-obese group, the visfatin, BMI, diastolic blood pressure, hirsutism F-G score, FSH, LH, T, hs-CRP and TG in obese group were significantly higher, the HDL-C in obese group were significantly lower, and there were statistical differences (P<0.01 or <0.05). In PCOS group, serum visfatin level was positively correlated with BMI, diastolic blood pressure, hirsutism F-G score, FSH, LH, T, hs-CRP and TG, and serum visfatin level was negatively correlated with HDL-C (P<0.05). Stepwise multiple linear regression analysis showed that diastolic blood pressure and TG increased were the main predictors of increased visfatin level in patients with PCOS (P < 0.05).@*Conclusions@#Serum visfatin is increased in the patients with PCOS, and serum visfatin is positively related with the cardiovascular risk factors.
ABSTRACT
@#AIM: To observe the effects of high glucose-induced environment on Visfatin expression in human retinal pigment epithelial cells and to study the effects of Polyphyllin I on Visfatin expression in high glucose environment. <p>METHODS: Human retinal pigment epithelial cells were cultured in three groups, normal control group, high glucose group and intervention group of high glucose aggravated PolyphyllinⅠ, testing after 12h of intervention culture. Normal control group:5.5mmol/L glucose concentration routine culture; high glucose group:25mmol/L high glucose was added to the medium to establish the model; high glucose aggravated PolyphyllinⅠdrug intervention group: high glucose 25mmol/L, 3μg/L PolyphyllinⅠdrug was added to the medium. Immunofluorescence staining assays to observe expression of the Visfatin and VEGF in human retinal pigment epithelial cells; real-time PCR assays for relative expression of Visfatin and VEGF mRNA in epithelial cells; and western-blot assays for Visfatin and VEGF proteins in epithelial cells. <p>RESULTS: Immunofluorescence detection revealed that Visfatin and VEGF were weakly positive in normal retinal pigment epithelial cells. Visfatin and VEGF were strongly positive in high glucose group. Visfatin and VEGF fluorescence in the drug intervention group was significantly weakened in the higher sugar group. RT-PCR showed that the expression level visfatin mRNA high sugar group was significantly higher than that of normal group and intervention group(<i>t</i>=4.24, 3.89, <i>P</i><0.05). VEGF mRNA expression was significantly higher in high glucose group than in normal group and intervention group(<i>t</i>=3.53, 2.57, <i>P</i><0.05). Western-blot results showed that the protein expression of visfatin and VEGF in high sugar group was significantly higher than that in control group and intervention group(<i>t</i>=3.62, <i>P</i>=0.01; <i>t</i>=3.79, <i>P</i><0.01). <p>CONCLUSION: The high glucose environment can stimulate the increased expression of Visfatin in retinal pigment epithelial cells, Polyphyllin I can inhibit the expression of Visfatin in retinal pigment epithelial cells in high glucose environment, which may provide a new idea for the treatment of diabetic retinopathy.
ABSTRACT
BACKGROUND: Visfatin has an insulin-like hypoglycemic effect with positive significance in the treatment of type 2 diabetes. Different exercise intensities have different effects on the level of visfatin. OBJECTIVE: To observe the effects of 6-week aerobic exercise of different intensities on glucose metabolism and the level of visfatin in type 2 diabetic rats and to explore the relationship between them. METHODS: The male Sprague-Dawley rats were fed with high-fat diet and injected with streptozotocin to establish a type 2 diabetes model. The 43 model rats were randomly divided into quiet control group (n=10), exercise group I (n=11), exercise group II (n=11) and exercise group III (n=11). The exercise intensities of the three exercise groups were 10, 15, and 20 m/min, respectively. Exercises of different intensities were performed 1 h/d, 5 days per week, for 6 continuous weeks. Blood samples were collected at the end of 6 weeks for determination of glucose metabolism-related indicators and serum and visceral levels of visfatin. RESULTS AND CONCLUSION: The indexes related to glucose metabolism (fasting blood glucose, glycosylated serum protein, insulin, insulin resistance index, etc.) in the three exercise groups were improved. The serum level of visfatin in the exercise groups I and II were significantly decreased (P 0.05). There was a significant decrease in visfatin level in the three exercise groups (P < 0.05), especially in the exercise group II (P < 0.01). The results indicate that low-intensity aerobic exercise can effectively improve insulin resistance and reduce blood glucose concentration in type 2 diabetic rats, and it is related to the loss of visceral fat and the reduction of visfatin secretion, where visfatin may play a positive role.
ABSTRACT
The aim of the study is to identify the effects and underlying mechanisms of visfatin on inflammation and necroptosis in vascular endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with visfatin or pretreated with Polyinosinic acid (LOX-1 inhibitor). By using the Western blot, RT-PCR, immunocytochemistry, enzyme-linked immunosorbent assay (ELISA), MTT and flow cytometry technique, the occurrence of inflammation and necroptosis in HUVECs were evaluated. Our results showed that 100 ng/mL visfatin significantly increased the mRNA and protein expression of monocyte chemotactic protein 1 (MCP-1) and LOX-1 after 24 hours' treatment in HUVECs. However, pretreatment with Polyinosinic acid could significantly reduce the expression of MCP-1 compared with visfatin group. Additionally, 100 ng/mL visfatin could induce the production of necrotic features and increase the mRNA expression of BMF (one of the markers of necroptosis), while pretreating with Polyinosinic acid markedly downregulated the mRNA expression of BMF gene and promoted the cell proliferation. These results indicate that visfatin might induce inflammation and necroptosis via LOX-1 in HUVECs, suggesting that visfatin plays a central role in the development of atherosclerosis.
Subject(s)
Humans , Cells, Cultured , Human Umbilical Vein Endothelial Cells , Inflammation/chemically induced , Necroptosis , Nicotinamide Phosphoribosyltransferase , Scavenger Receptors, Class E/geneticsABSTRACT
Objective To explore the correlation between serum visfatin level and cardiovascular disease risk factors in patient with polycystic ovary syndrome (PCOS).Methods A total of 100 PCOS patients (PCOS group) and 50 healthy women (control group) in Wuhan Puren Hospital from July 2016 to July 2018 were selected.In addition,according to the body mass index (BMI),the PCOS patients were divided into obese group (BMI ≥ 25 kg/m2,57 cases) and non-obese group (BMI < 25 kg/m2,43 cases).Serum level of visfatin was measured by enzyme-linked immunosorbent assay (ELISA) method,and the correlation between serum visfatin and follicle-stimulating hormone (FSH),luteinizing hormone (LH),testesterone (T),high sensitivity C-reactive protein (hs-CRP),blood lipids and blood glucose was analyzed.Results Compared with those in control group,the visfatin,BMI,diastolic blood pressure,waist and hip rate,hirsutism F-G score,FSH,LH,T,triglyeride (TG),fasting insulin (FINS),homeostasis model of assessment for insulin resistance index (HOMA-IR) in PCOS group were significantly increased:(103.20 ± 19.15) μg/L vs.(29.56 ± 4.14) μg/L,(25.81 ± 4.17) kg/m2 vs.(21.29 ± 3.74) kg/m2,(81.91 ± 10.32) mmHg (1 mmHg =0.133 kPa) vs.(68.29 ± 7.57) mmHg,0.91 ± 0.14 vs.0.82 ± 0.13,(13.41 ± 2.91) scores vs.(5.98 ± 1.01) scores,(12.78 ± 1.98) U/L vs.(11.95 ± 1.51) U/L,(15.84 ± 3.16) U/L vs.(12.94 ± 1.53) U/L,(2.98 ± 0.32) nmol/L vs.(1.17 ± 0.20) nmol/L,(1.89 ± 0.43) mmol/L vs.(1.21 ± 0.11) mmol/L,(18.40 ± 2.98) mU/L vs.(11.23 ± 2.10) mU/L,4.25 ± 0.86 vs.2.51 ± 0.55;the high density lipoprotein-cholesterol (HDL-C) and ISI were significantly decreased:(1.46 ± 0.23) mmol/L vs.(1.55 ± 0.27) mmol/L and 0.011±0.002 vs.0.019 ± 0.005,and there were statistical differences (P < 0.01 or < 0.05).In addition,compared with those in non-obese group,the visfatin,BMI,diastolic blood pressure,hirsutism F-G score,FSH,LH,T,hs-CRP and TG in obese group were significantly higher,the HDL-C in obese group were significantly lower,and there were statistical differences (P< 0.01 or < 0.05).In PCOS group,serum visfatin level was positively correlated with BMI,diastolic blood pressure,hirsutism F-G score,FSH,LH,T,hs-CRP and TG,and serum visfatin level was negatively correlated with HDL-C (P < 0.05).Stepwise multiple linear regression analysis showed that diastolic blood pressure and TG increased were the main predictors of increased visfatin level in patients with PCOS (P < 0.05).Conclusions Serum visfatin is increased in the patients with PCOS,and serum visfatin is positively related with the cardiovascular risk factors.
ABSTRACT
@#Objective Visfatin, a newly identified pro-inflammatory adipokine, has been related to atherosclerosis,therefore we explore the association between the visfatin rs61330082 and ischemic stroke risk. The -1535 polymorphism (rs61330082) located in the visfatin gene promoter is reportedly associated with inflammatory related atherosclerosis. Method A total of 368 ischemic stroke patients and 381 healthy controls were enrolled for the study. The rs61330082 polymorphism was genotyped by the polymerase chain reaction-ligase detection reaction (PCR-LDR) sequencing method. Results No significant differences in genotypic and allelic frequencies between ischemic stroke patients and healthy controls were observed even when the OR was adjusted for the clinical variables. We also did not find any significant association from sex subtypes. Conclusion Visfatin rs61330082 polymorphism is not associated with ischemic stroke risk in the northern Chinese Han population.
ABSTRACT
Background: Adipocytokines have been recently implicated in the pathogenesis of preeclampsia. Visfatin is one of such adipokines.Objective: To determine the association between serum visfatinlevels and preeclampsia.Methods:A prospective, case-control study was carried out in 160 pregnant womenconsisting of80 pre-eclamptics and 80 normotensive controls, matched for age and parity during the third trimester. Maternal serum visfatinlevels were determined in both groups using a visfatin (Human) enzyme-linked immunosorbent assay. Serum Visfatin levels were compared between the groups and correlated to the blood pressure, proteinuria,fetal birth weight and Apgar scores.Results:The mean serum visfatin level was significantly higher (10.3±6.9ng/ml)in preeclampsia than (7.4±4.4ng/ml) in the control group (p=0.001). The mean serumvisfatin level was higher in severe pre-eclamptics (10.8±8.9ng/ml) compared to (9.6±5.8ng/ml)in mild preeclamptics and this was statistically significant (p=0.021).Visfatin levels showed a negative and non-significant correlation with both systolic (r= -0.011 and p=0.924), diastolic blood pressure(r= -0.012, p=0.913) and body mass index (r= -0.142, p=0.209) in both study and control groups. Mean birth weight was significantly lower in the preeclampsia (2.8±0.25kg) compared to the control group (3.2±0.31kg) P=0.000. The mean birthweight was lower in severe preeclampsia (2.7±0.25kg compared to 2.9±0.39 in mild preeclamsia. There was no significant correlation between the visfatin levels and Apgar score at 5minutes and birth weights in both groups (P=>0.05).Conclusion:This study showed a significant increase in the level of visfatin in preeclampsiacompared to their normo-tensive controls. However, this increased level was not consistent with the severity of the disease.